IDEAYA Biosciences and Servier announced promising Phase 2/3 trial results for darovasertib, a selective PKC inhibitor, combined with crizotinib in the treatment of metastatic uveal melanoma. According to BioSpace.com, the combination therapy demonstrated what industry analysts are calling a “best-in-class efficacy profile,” more than doubling progression-free survival compared to standard treatment approaches and positioning the partnership for FDA submission in the second half of 2026.
Significant Clinical Advantage
The OptimUM-02 registrational trial demonstrated compelling efficacy metrics that exceeded current treatment standards. Patients receiving darovasertib plus crizotinib achieved a median progression-free survival of 6.9 months compared to 3.1 months for those receiving investigator’s choice of therapy (ICT), more than doubling the time before disease progression.
The trial enrolled 210 patients with HLA-A*02:01-negative metastatic uveal melanoma in the combination therapy arm and 103 in the control arm. The ICT group reflected real-world clinical practice, comprising 78 patients on Bristol Myers Squibb’s Yervoy and Opdivo combination and 25 patients receiving Merck’s Keytruda immunotherapy.
Beyond progression-free survival, the combination therapy delivered impressive response rates. The overall response rate reached 37.1% for the darovasertib-crizotinib group compared to just 5.8% for the ICT arm, with five patients achieving complete response, a particularly notable achievement in this challenging malignancy.
Safety and Tolerability
The therapeutic combination maintained a manageable safety profile consistent with previously reported adverse events, with no unexpected safety signals emerging from the trial data. This favorable tolerability profile enhances the clinical utility of the treatment, particularly important for patients with metastatic disease who require durable therapy.
An Unmet Medical Need Addressed
Currently, no FDA-approved systemic therapies exist for primary positive uveal melanoma or for patients specifically with HLA-A*02:01-negative metastatic uveal melanoma. Darovasertib represents a significant advancement addressing this critical treatment gap, offering the first potential standard-of-care option for this patient population.
Path to Patients
With regulatory submission planned for the second half of 2026, darovasertib-crizotinib could become available to metastatic uveal melanoma patients facing limited treatment options. The trial’s positive outcomes and regulatory pathway demonstrate the continued importance of targeted therapies and kinase inhibitor combinations in advancing precision oncology for rare cancers. The partnership’s success could establish a new treatment paradigm for this aggressive malignancy while offering hope to patients with previously limited therapeutic alternatives.
